Rheumatology International

, Volume 34, Issue 10, pp 1369–1378

Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study

  • Wan-Hee Yoo
  • Han-Gyul Yoo
  • Sung-Hwan Park
  • Han-joo Baek
  • Yun Jong Lee
  • Seung Cheol Shim
  • Seong Wook Kang
  • Hyun Ah Kim
  • Jung Soo Song
  • Chang Hee Suh
  • Sung Jae Choi
  • Bo Young Yoon
  • Dong Nyeon Tae
  • Hyun Sook Ko
  • Yeong-Wook Song
Original Article

DOI: 10.1007/s00296-014-2964-8

Cite this article as:
Yoo, WH., Yoo, HG., Park, SH. et al. Rheumatol Int (2014) 34: 1369. doi:10.1007/s00296-014-2964-8

Abstract

The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla®) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient’s global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA.

Keywords

Knee osteoarthritis PG201 Celecoxib 

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Wan-Hee Yoo
    • 1
    • 2
  • Han-Gyul Yoo
    • 3
  • Sung-Hwan Park
    • 4
  • Han-joo Baek
    • 5
  • Yun Jong Lee
    • 6
  • Seung Cheol Shim
    • 7
  • Seong Wook Kang
    • 8
  • Hyun Ah Kim
    • 9
  • Jung Soo Song
    • 10
  • Chang Hee Suh
    • 11
  • Sung Jae Choi
    • 12
  • Bo Young Yoon
    • 13
  • Dong Nyeon Tae
    • 14
  • Hyun Sook Ko
    • 14
  • Yeong-Wook Song
    • 15
  1. 1.Department of Internal Medicine, Medical SchoolChonbuk National UniversityJeonjuKorea
  2. 2.Research Institute of Clinical Medicine, Chonbuk National University HospitalChonbuk National UniversityJeonjuKorea
  3. 3.Department of Pharmacy PracticeUniversity of Rhode IslandKingstonUSA
  4. 4.College of MedicineThe Catholic University of KoreaSeoulKorea
  5. 5.Gachon University of Medicine and ScienceIncheonKorea
  6. 6.Bundang HospitalSeoul National UniversitySeoulKorea
  7. 7.School of MedicineEulji UniversityDaejeonKorea
  8. 8.School of MedicineChungnam National UniversityDaejeonKorea
  9. 9.Sacred Heart HospitalHallym UniversityAnyangKorea
  10. 10.College of MedicineChung-Ang UniversitySeoulKorea
  11. 11.School of MedicineAjou UniversitySuwonKorea
  12. 12.College of MedicineKorea UniversityAnsanKorea
  13. 13.Ilsan Paik HospitalInje UniversityGoyangKorea
  14. 14.PMG Pharm Co, Ltd.AnsanKorea
  15. 15.Department of Internal MedicineSeoul National University HospitalSeoulKorea

Personalised recommendations